{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:42:41Z","timestamp":1792154561191,"version":"4.4.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.00829","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T04:43:48Z","timestamp":1597207428000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Gianluca","family":"D'Onofrio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Kuchenbuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hachon-Le Camus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Desnous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Staath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Napuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doroth\u00e9e","family":"Ville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Pedespan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"L\u00e9pine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Cances","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"de Saint-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9o","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Milh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Nabbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"B1","unstructured":"FDA Approves First Drug Comprised of an Active Ingredient Derived From Marijuana to Treat Rare, Severe Forms of Epilepsy.2018"},{"key":"B2","unstructured":"R\u00e9f\u00e9rentiel des ATU Nominatives"},{"key":"B3","unstructured":"Epidyolex2020"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s40265-019-01171-4","article-title":"Pharmacological and therapeutic properties of cannabidiol for epilepsy","volume":"79","author":"Franco","year":"2019","journal-title":"Drugs."},{"key":"B5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/epi.14628","article-title":"Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial","volume":"60","author":"Devinsky","year":"2019","journal-title":"Epilepsia."},{"key":"B12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/epi.14670","article-title":"Cannabidiol in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study","volume":"60","author":"Thiele","year":"2019","journal-title":"Epilepsia."},{"key":"B13","unstructured":"Treatment in patients with seizures associated with tuberous sclerosis complex: a randomized, double-blind, placebo-controlled phase 3 trial (GWPCARE6)\n            ThieleE\n            BebinEM\n            BhathalH\n            JansenF\n            Kotulska-J\u00f3zwiakK\n            LawsonJA\n          23158522Baltimore, MDAmerican Epilepsy Society AESAES 2019 Annual Meeting Abstract Database2019"},{"key":"B14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatmentresistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/epi.14477","article-title":"Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results","volume":"59","author":"Szaflarski","year":"2018","journal-title":"Epilepsia."},{"key":"B17","unstructured":"GreenwichBiosciences\n          Highlights of Prescribing Information - Epidiolex2018"},{"key":"B18","unstructured":"Guidance for Industry Drug-Induced Liver Injury : Premarketing Clinical Evaluation2009"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.seizure.2004.04.009","article-title":"Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures","volume":"13","author":"Faught","year":"2004","journal-title":"Seizure."},{"key":"B20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1592\/phco.19.1.88.30515","article-title":"Slowing the initial titration rate of tramadol improves tolerability","volume":"19","author":"Ruoff","year":"1999","journal-title":"Pharmacotherapy."},{"key":"B21","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1440-1819.2010.02136.x","article-title":"Slow vs standard up-titration of paroxetine in the treatment of panic disorder: a prospective randomized trial","volume":"64","author":"Buoli","year":"2010","journal-title":"Psychiatry Clin Neurosci."},{"key":"B22","unstructured":"An open-label study of topiramate as add-on therapy for epilepsy using slow titration99104\n            LiaoW-P\n            YangS-Q\n            YiY-H\n            DengY-H\n            LiB-M\n            PanY\n          Neurol Asia102005"},{"key":"B23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.4088\/JCP.v66n0516","article-title":"Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash","volume":"66","author":"Ketter","year":"2005","journal-title":"J Clin Psychiatry."},{"key":"B24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.56.6.743","article-title":"Rapid initiation of gabapentin: a randomized, controlled trial","volume":"56","author":"Fisher","year":"2001","journal-title":"Neurology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.pupt.2014.01.005","article-title":"Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view","volume":"27","author":"Saturni","year":"2014","journal-title":"Pulm Pharmacol Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin Pharmacol Drug Dev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia."},{"key":"B28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1528-1157.43.s.3.5.x","article-title":"Children versus adults: pharmacokinetic and adverse-effect differences","volume":"43","author":"Anderson","year":"2002","journal-title":"Epilepsia."},{"key":"B29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/DHPS.S28821","article-title":"Specific safety and tolerability considerations in the use of anticonvulsant medications in children","volume":"4","author":"Wirrell","year":"2012","journal-title":"Drug Healthc Patient Saf."},{"key":"B30","doi-asserted-by":"publisher","first-page":"102402","DOI":"10.1016\/j.ctim.2020.102402","article-title":"Safety and pharmacokinetics of medical cannabis preparation in a monocentric series of young patients with drug resistant epilepsy","volume":"51","author":"Gherzi","year":"2020","journal-title":"Complement Ther Med."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00829\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T04:43:53Z","timestamp":1597207433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00829\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":30,"alternative-id":["10.3389\/fneur.2020.00829"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00829","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"article-number":"829"}}